Eli Lilly (LLY +1.06%) is one of today's biggest players in the erectile dysfunction space. Its drug Cialis garnered more than $1.9 billion in 2012, but how important is this single therapeutic to Lilly's total business? What are the competitive dynamics of the erectile dysfunction market, and how do Pfizer's (PFE 0.20%) Viagra and VIVUS' (VVUS +0.00%) drug Stendra compare to Cialis? In this video, health care analyst Max Macaluso examines these issues for investors.
Who are the key players in the erectile dysfunction space?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo